Home > Boards > US OTC > Miscellaneous > Enzolytics Inc. (ENZC)

Love this from Bioclonetics website: BioClonetics specializes in

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
3freebee Member Profile
Followed By 6
Posts 373
Boards Moderated 0
Alias Born 11/12/19
160x600 placeholder
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
WSGF's, Vaycaychella, Heats Up In $32 Billion Caribbean Vacation Market; Adds Six-Room Hotel To Portfolio Interests InvestorsHub NewsWire - 1/22/2021 9:48:20 AM
Epazz, Inc. (OTC Pink: EPAZ) Enters Blockchain and Cryptocurrency InvestorsHub NewsWire - 1/12/2021 6:00:00 AM
The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM
Epazz, Inc. (OTC Pink: EPAZ) Emerging in Blockchain and Cryptocurrency InvestorsHub NewsWire - 1/6/2021 6:00:00 AM
Epazz, Inc. (OTC Pink: EPAZ) Tapping Blockchain & Cryptocurrency with IEO InvestorsHub NewsWire - 12/30/2020 6:00:00 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
Penny Stocks on the Move: SFOR and WSGF InvestorsHub NewsWire - 12/10/2020 3:38:16 PM
TNS is on the Hunt for the Next OTC Home Run Stock, Feature Report InvestorsHub NewsWire - 11/30/2020 8:20:00 AM
PURA Launches Hemp Farming Co-Op Campaign InvestorsHub NewsWire - 11/23/2020 1:36:12 PM
ATDS - Cloud Computing Data Security Leader Data443 Eliminates 300M Warrants Removing Overhang For PPS Appreciation And Uplist InvestorsHub NewsWire - 11/18/2020 2:27:56 PM
Epazz, Inc. (OTC Pink: EPAZ) - Expands Internationally Sales will be seen on Q3 Financials InvestorsHub NewsWire - 11/6/2020 6:03:06 AM
ATDS Q3 RPT Likely To Trigger PPS Rebound InvestorsHub NewsWire - 10/30/2020 11:30:04 AM
ATDS Breakout Is Inevitable - Q3 Filing Could Be Trigger InvestorsHub NewsWire - 10/21/2020 1:00:08 PM
Epazz, Inc. (OTC Pink: EPAZ) - Healthcare & Government Contracts and now Education InvestorsHub NewsWire - 9/22/2020 6:25:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/16/2020 6:05:35 AM
3freebee   Sunday, 12/27/20 09:58:14 PM
Re: None
Post # of 85092 
Love this from Bioclonetics website: BioClonetics specializes in creation of human neutralizing monoclonal antibodies, not "humanized" mouse or rat counterparts, as are the majority of mAb therapeutics in pharmaceutical use today. BioClonetics’ technological methodologies have developed an effective, strong and robust portfolio of biologics that have pharmaceutical application with significant benefits to patients or animals in the global marketplace. From an identified and created parent hybridoma cell line, four distinct and effective products can be produced: (1) fully human neutralizing monoclonal antibody—directed against any pathogen based disease entity—through use in passive immunotherapy; (2) an effective humoral active vaccine that is safe and effective; (3) an oral mini-antibody peptide based medication with an efficacy that is equivalent to the immunologic capacity of the monoclonal antibody produced by parent hybridoma cell; and (4) an entry-fusion inhibitor that is immunologic in character and scope. The applications are broad, effective and beneficial for immunotherapeutic use.

The methodologies and processes for creating immortalized cells that stably produce human monoclonal antibodies is a company proprietary trade secret. BioClonetics is amenable to discussing licensing the innovational technique of cloning the immune system of any species in the animal kingdom.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences